Cutia Therapeutics (2487.HK)

7,350 +0,240 (+3,38%) Alla chiusura: 04:08PM HKT

Cutia Therapeutics

Huanzhi Building
20th Floor 436 Heng Feng Road Jingan District
Shanghai 200070
China
86 21 5298 2688
https://www.cutiatx.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 298

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Ms. Lele Zhang	Founder, CEO & Executive Director	4,57M	N/D	1977
Mr. Yuqing Huang	CFO & Executive Director	7,7M	N/D	1990
Mr. Qi Zhu	Chief Medical Officer	N/D	N/D	1973
Dr. Lei Lei	Senior Vice President of Research & Development Department	N/D	N/D	1985
Ms. Chunna Zhang	Senior Vice President of Regulatory Affairs Department	N/D	N/D	1979
Ms. Jingxin Xu	Senior Vice President of Manufacturing & Quality Control Department	N/D	N/D	1979
Mr. Jiaru Wu	Senior Vice President of Finance & Integrated Management Department	N/D	N/D	1984
Ms. Sze Ting Chan A.C.S.	Company Secretary	N/D	N/D	1982

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in HKD.

Descrizione

Cutia Therapeutics an investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People's Republic of China and Hong Kong. It focuses on the dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. The company's products include CU-40102, a topical finasteride spray approved for androgenetic alopecia treatment; CU-10201, a topical 4% minocycline foam, approved for acne vulgaris treatment; and CU-10101, a topical novel small molecule agent, and a non-hormonal and small molecule drug for the treatment of mild to moderate atopic dermatitis. It is also involved in the development of CU-20401, a recombinant mutant collagenase, currently under Phase II clinical trial for submental adipose accumulation (submental fat); CU-40101, a topical small molecule thyroid hormone receptor agonist liniment, currently completed Phase I clinical trial for the treatment of androgenetic alopecia; and CU-30101, a localized topical lidocaine and tetracaine compound topical anesthesia cream, completed Phase III clinical trial for surface dermatologic operations. The company was incorporated in 2019 and is headquartered in Shanghai, China.

Governance aziendale

L'ISS Governance QualityScore di Cutia Therapeutics al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.